Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

This study tests whether platinum and taxane chemotherapy (a standard chemotherapy combination) works in patients with metastatic castration-resistant prostate cancer (cancer that continues to grow despite low testosterone) who have specific inherited or acquired DNA repair gene mutations, such as BRCA1, BRCA2, or ATM. **You may be eligible if...** - You have prostate cancer that is metastatic and no longer responding to hormone therapy (castration-resistant) - Your tumor or blood testing has confirmed a qualifying DNA repair gene mutation (e.g., BRCA1, BRCA2, ATM, CDK12, or similar) - You have previously received an advanced hormone therapy (ARPI) such as enzalutamide, abiraterone, or apalutamide - Your testosterone levels are below 50 ng/dL (castration levels) - Your cancer has progressed on imaging or via rising PSA levels **You may NOT be eligible if...** - Your cancer has neuroendocrine or small cell features - You have not yet recovered from prior treatment toxicities - You have not had adequate washout time from prior therapies Talk to your doctor to see if this trial is right for you.